Researchers in Japan were able to transfer genes from jellyfish into common fruit flies and discovered that the transferred gene suppressed an age-related intestinal issue in the flies. The findings suggest that studying genes specific to animals with high regenerative capability like jellyfish may uncover new mechanisms for rejuvenating stem cell function and extending the healthy lifespan of unrelated organisms. Read More
Big pharma continues to invest heavily into molecular glue degraders. The latest deal has Eisai Co. Ltd. striking up a research collaboration that could bring Seed Therapeutics Inc. up to $1.5 billion in up-front and milestone payments. The two said they plan to discover, develop and commercialize MGDs for several undisclosed neurodegeneration and oncology targets. Read More
Researchers from Merck & Co Inc. have presented preclinical data for the novel Nav1.8 inhibitor MSD-199, being developed for the treatment of inflammatory and neuropathic pain. Read More
IFM Due Inc. has divulged stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer. Read More
Shinobi Therapeutics Inc. has been awarded non-dilutive grant funding of up to $59 million by the Japanese Agency for Medical Research and Development (AMED). Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
A spontaneous homozygous deletion affecting the copy number of the cadherin 23 (Cdh23) gene in a line of laboratory mice gave rise to a new murine model with hereditary hearing loss and vestibular alterations. Read More
Cerevel Therapeutics Inc. has identified compounds acting as muscarinic M4 receptor agonists reported be useful for the treatment of pain, sleep disorders, schizophrenia, substance abuse and dependence, drug-induced dyskinesia, and Alzheimer's and Parkinson's disease. Read More
Tiumbio Co. Ltd. has prepared and tested cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer, inflammation and fibrosis. Read More
Researchers from Mustbio Co. Ltd. and Chung-Ang University have presented the discovery and preclinical characterization of MB-2033, a novel bispecific fusion protein being developed for the treatment of cancer. Read More
Cogent Biosciences Inc. has disclosed compounds acting as fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of achondroplasia, cancer, craniosynostosis, Alzheimer's disease, fibrosis, pulmonary fibrosis, systemic scleroderma (systemic sclerosis) and thanatophoric dysplasia, among others. Read More
Astrazeneca AB has described transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of cancer, hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, diabetes, epilepsy, multiple sclerosis, osteoarthritis and inflammatory disorders. Read More
Nammi Therapeutics Inc. has announced a $1 million investment commitment by the Myeloma Investment Fund (MIF) in a $30 million series B financing round prior to the planned start of a first-in-human phase I study of the company’s QXL-138AM in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma. Read More
